Affiliations: [a] Department of General Surgery, First Affiliated Hospital, Medical School of Xi'an Jiaotong University, Xi'an Shaanxi, People's Republic of China | [b] Division of Gastroenterology and Hepatology, University of Michigan School of Medicine, Ann Arbor, MI, USA
Correspondence:
[*]
Corresponding author: Thomas D. Wang, MD, PhD, Division of Gastroenterology and Hepatology, University of Michigan School of Medicine, 109 Zina Pitcher Place, BSRB 1522, Ann Arbor, MI 48109, USA. E-mail: [email protected].
Abstract: The emergence of in vivo cancer biomarkers is promising tool for early detection, risk stratification, and therapeutic intervention in the esophagus, where adenocarcinoma is increasing at a rate that is faster than any other in industrialized nations. Exciting advances in target identification, probe development, and optical instrumentation are creating tremendous new opportunities for advancing techniques of molecular imaging. Progress in these areas is being made with small animal models of esophageal cancer using surgical approaches to induce reflux of acid and bile, and these findings are beginning to be evaluated in the clinic. Further identification of relevant targets, characterization of specific probes, and development of endoscopic imaging technologies are needed to further this direction in the field of molecular medicine. In the future, new methods that use in vivo cancer biomarkers for the early detection of neoplastic changes in the setting of Barrett's esophagus will become available.
Keywords: Esophagus, adenocarcinoma, biomarkers, peptides, rat, endoscopy
